title: Experimental stimulation of bone healing with teriparatide: histomorphometric and microhardness analysis in a mouse model of closed fracture.
abstract: Fracture consolidation is a crucial goal to achieve as early as possible, but pharmacological stimulation has been neglected so far. Teriparatide has been considered for this purpose for its anabolic properties. We set up a murine model of closed tibial fracture on which different doses of teriparatide were tested. Closed fracture treatment avoids any bias introduced by surgical manipulations. Teriparatide's effect on callus formation was monitored during the first 4 weeks from fracture. Callus evolution was determined by histomorphometric and microhardness assessment. Daily administration of 40 μg/kg of teriparatide accelerated callus mineralization from day 9 onward without significant increase of sizes, and at day 15 the microhardness properties of treated callus were similar to those of bone tissue. Teriparatide considerably improved callus consolidation in the very early phases of bone healing.
authors.affiliation: Department of Clinical and Biological Sciences, University of Turin, Reg. Gonzole 10, Orbassano, TO, Italy.
authors.forename: Barbara
authors.initials: B
authors.lastname: Mognetti
authors.forename: Silvia
authors.initials: S
authors.lastname: Marino
authors.forename: Alessandro
authors.initials: A
authors.lastname: Barberis
authors.forename: Anne-Sophie Bravo
authors.initials: AS
authors.lastname: Martin
authors.forename: Yohann
authors.initials: Y
authors.lastname: Bala
authors.forename: Francesco
authors.initials: F
authors.lastname: Di Carlo
authors.forename: Georges
authors.initials: G
authors.lastname: Boivin
authors.forename: Michele Portigliatti
authors.initials: MP
authors.lastname: Barbos
mesh_terms: D000818:Animals; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use; D001842:Bone and Bones / Q000000981:diagnostic imaging / Q000187:drug effects / Q000648:ultrastructure; D004353:Drug Evaluation, Preclinical; D005260:Female; D017102:Fracture Healing / Q000187:drug effects*; D005596:Fractures, Closed / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D006244:Hardness / Q000187:drug effects* / Q000502:physiology; D006245:Hardness Tests; D051379:Mice; D013268:Stimulation, Chemical; D019379:Teriparatide / Q000494:pharmacology / Q000627:therapeutic use*; D013978:Tibial Fractures / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D015854:Up-Regulation / Q000187:drug effects; D055114:X-Ray Microtomography
chemical_list: D050071:Bone Density Conservation Agents; D019379:Teriparatide